Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Benzo[D]Isoxazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzo[D]Isoxazole SCHEMBL5697378 | 0.87 | NPC1 (0.40) | SMN1; SMN2LMNANPC1RAB9AGAA | |
| Benzo[D]Isoxazole SCHEMBL5773958 | 0.87 | TDP1 (0.34) | LMNANPC1RAB9APTGS2GAA | |
| Benzo[D]Isoxazole SCHEMBL5918862 | 0.86 | NPC1 (0.39) | SMN1; SMN2LMNANPC1RAB9AGAA | |
| Benzo[D]Isoxazole SCHEMBL6298798 | 0.86 | RAB9A (0.39) | SMN1; SMN2LMNANPC1RAB9AGAA | |
| Benzo[D]Isoxazole SCHEMBL5697384 | 0.86 | NPC1 (0.39) | SMN1; SMN2LMNANPC1RAB9AGAA | |
| Benzo[D]Isoxazole SCHEMBL1355530 | 0.82 | — | — | |
| Benzo[D]Isoxazole SCHEMBL8438 | 0.82 | — | — | |
| Benzo[D]Isoxazole SCHEMBL29366929 | 0.82 | — | — | |
| Benzo[D]Isoxazole SCHEMBL5773956 | 0.81 | TDP1 (0.35) | SMN1; SMN2LMNANPC1RAB9ATDP1 | |
| Benzo[D]Isoxazole SCHEMBL27515218 | 0.81 | CA12 (0.35) | SMN1; SMN2LMNANPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287535-A1 | Process for the manufacture of 1,2-benzisoxazole-3-methanesulphonamide | WOCKHARDT LIMITED | 2006-12-21 | — | — | US | claimed |
| EP-1682522-A1 | A PROCESS FOR THE MANUFACTURE OF ZONISAMIDE | Wockhardt Limited (IN) | 2006-07-26 | — | — | EP | claimed |
| US-6936720-B2 | Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-08-30 | — | — | US | claimed |
| WO-2005044808-A1 | A PROCESS FOR THE MANUFACTURE OF ZONISAMIDE | WOCKHARDT LIMITED (IN) | 2005-05-19 | — | — | WO | claimed |
| US-20060287535-A1 | Process for the manufacture of 1,2-benzisoxazole-3-methanesulphonamide | WOCKHARDT LIMITED | 2006-12-21 | — | — | US | disclosed |
| EP-1682522-A1 | A PROCESS FOR THE MANUFACTURE OF ZONISAMIDE | Wockhardt Limited (IN) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005044808-A1 | A PROCESS FOR THE MANUFACTURE OF ZONISAMIDE | WOCKHARDT LIMITED (IN) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287535-A1 | Process for the manufacture of 1,2-benzisoxazole-3-methanesulphonamide | GABRE, CA3, GABRA1 | MAOB 2963/4885CYP3A4 205/4885BLM 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.